OncoTargets and Therapy (Apr 2020)
PCSK1 Overexpression in Rectal Cancer Correlates with Poor Response to Preoperative Chemoradiotherapy and Prognosis
Abstract
Chia-Lin Chou,1,2 Tzu-Ju Chen,2– 4 Cheng-Yi Lin,5 Sung-Wei Lee,6 Shih-Chang Wang,7 Shou-Sheng Chu,7 Ching-Chieh Yang7,8 1Division of Colon and Rectal Surgery, Department of Surgery, Chi Mei Medical Center, Tainan, Taiwan; 2Institute of Biomedical Sciences, National Sun Yat-sen University, Kaohsiung, Taiwan; 3Department of Pathology, Chi Mei Medical Center, Tainan, Taiwan; 4Department of Optometry, Chung Hwa University of Medical Technology, Tainan, Taiwan; 5Division of Gastroenterology and Hepatology, Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan; 6Department of Radiation Oncology, Chi Mei Medical Center, Liouying, Tainan, Taiwan; 7Department of Radiation Oncology, Chi Mei Medical Center, Tainan, Taiwan; 8Department of Pharmacy, Chia-Nan University of Pharmacy and Science, Tainan, TaiwanCorrespondence: Ching-Chieh YangDepartment of Radiation Oncology, Chi-Mei Medical Center, No. 901 Zhonghua Road, Yung Kang District, Tainan City 701, TaiwanTel +88662812811-53501Email [email protected]: In a data mining search for potential therapeutic targets to improve the outcome of rectal cancer, we identified PCSK1 as the cell–cell signaling gene most significantly associated with poor response to concurrent chemoradiotherapy (CCRT). This study aims to investigate the prognostic value of PCSK1 expression in rectal cancer patients who underwent neoadjuvant CCRT.Methods: Endoscopic biopsy specimens from 172 rectal cancer patients receiving neoadjuvant CCRT followed by curative surgery were assessed immunohistochemically for PCSK1 expression, and H-scores were determined. Expression levels of PCSK1 were further analyzed for correlations with clinicopathologic features, tumor regression grade, metastasis-free survival, disease-specific survival, and recurrence-free survival.Results: PCKS1 overexpression was significantly associated with pretreatment tumor status (T3– 4; p = 0.009), pretreatment nodal status (N1– 2; p < 0.001), posttreatment tumor status (T3– 4; p < 0.001), posttreatment nodal status (N1– 2; p < 0.001), vascular invasion (p = 0.003), and perineurial invasion (p = 0.023). PCKS1 overexpression was also found to be significantly associated with a lower degree of tumor regression (p < 0.001). In the univariate analysis, PCSK1 overexpression was significantly associated with lower disease-specific survival, metastasis-free survival, and recurrence-free survival (p < 0.005). PCSK1 overexpression remained an independent prognostic factor of lower disease-specific survival (p = 0.003; hazard ratio, 5.478) in the multivariate analysis.Conclusion: Determination of PCSK1 overexpression may be useful for identifying rectal cancer patients at risk for a poor response and worse survival after CCRT.Keywords: PCSK1, rectal cancer, chemoradiotherapy, response, survival
